Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Evolent Health, Inc. (EVH)

Evolent Health Q3 revenue rises to $725.4 million; lifts Adjusted EBITDA outlook

Positive Impact 4 of 5 earnings Written later

Evolent Health reported third-quarter 2026 revenue of $725.4 million, up from $479.5 million a year earlier, and a narrower net loss of $23.6 million, or $0.21 per share, versus $26.9 million, or $0.24 per share. The company raised its full-year 2026 Adjusted EBITDA guidance to $130.0 million to $135.0 million while reiterating its revenue guidance of $2.6 billion to $2.7 billion, though Adjusted EBITDA for the quarter fell to $34.3 million from $39.0 million.

Key points

  • Q3 2026 revenue $725.4 million vs. $479.5 million in Q3 2025; net loss attributable to common shareholders $23.6 million vs. $26.9 million
  • Adjusted EBITDA $34.3 million vs. $39.0 million; Adjusted EBITDA margin 4.7% vs. 8.1%; medical expense ratio 93.0% vs. 85.0%
  • 2026 Adjusted EBITDA guidance raised to $130.0 million to $135.0 million; revenue guidance reiterated at $2.6 billion to $2.7 billion
  • Cash and cash equivalents $148.3 million as of September 30, 2026

The filing

CompanyEvolent Health, Inc. (EVH)
Form8-K, current report
Filed with the SECNov 5, 2026, 7:10 AM ET
Accession number0001628908-26-000102

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.